Tuesday, April 30, 2024
4/30/2024
PROJECT SUMMARY/ABSTRACT Parkinson’s disease (PD) is a progressive neurodegenerative disease resulting from the loss of dopaminergic neurons in the substantia nigra. It is the second-leading neurodegenerative disease associated with aging. For over fifty years, treatment with levodopa (L-dopa), which crosses the blood-brain barrier and is converted to dopamine (DA), has been used to mitigate the debilitating motor symptoms associated with PD. However, there are several caveats associated with L-dopa therapy including erratic, “on-off” cyclical relief from motor symptoms, large individual variability in effective dose, and a loss of efficacy over time. This loss of efficacy necessitates escalation of L-dopa dosage, with an increased risk of L-dopa induced dyskinesia. One confounding factor in L- dopa treatment is its metabolism to DA by gut microbiota. DA produced systemically is unable to cross the blood- brain barrier and is associated with adverse physiological effects. Although aromatic amino acid decarboxylase inhibitors (e.g., carbidopa) are typically co-administered with L-dopa, they are ineffective against microbial metabolism. Enterococcus faecalis, a ubiquitous member of the gut microbiome that is primarily responsible for the bacterial metabolism of L-dopa, expresses a tyrosine decarboxylase (TyrDC) that avidly converts L-dopa to DA and is only weakly inhibited by carbidopa. In the proposed studies, we will test the hypothesis that deletion of the TyrDC gene from a previously engineered, bacteriocin-expressing strain of E. faecalis will abrogate L- dopa metabolism, leading to increased L-dopa and decreased DA in the serum, and elevated DA levels in the brain following oral L-dopa administration. In Aim 1, we will investigate colonization of the mouse gastrointestinal tract with the newly constructed ¿tyrDC mutant and determine the impact of colonization on L-dopa and DA concentrations in the blood and brain following oral administration of L-dopa. In Aim 2, we will address the impact of colonization with the ¿tyrDC mutant on the efficacy of oral L-dopa therapy in alleviating motor deficits and the development of L-dopa induced dyskinesia in a mouse model of PD. The scientific impact of these studies will be to further elucidate the effects of gut microbial metabolism on the efficacy of oral L-dopa therapy. There is a clear unmet need for novel approaches that enhance or extend the usefulness of L-dopa in PD treatment, and the development of a probiotic that effectively prevents decarboxylation of L-dopa in the gastrointestinal tract may have significant potential as an adjunct to L-dopa in the management of PD.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
